Consistency of Salivary Flow Rate and Xerostomia in Patients with Sjögren's Syndrome

doi:10.13701/j.cnki.kqyxyj.2023.08.016

Abstract

Abstract: Objective: To assess the consistency of salivary flow rate and xerostomia, and explore the risk factors for reduced salivary flow rate in patients with Sjögren's syndrome (SS). Methods: The clinical data of 151 patients with SS were collected, including a sensation of oral dryness (xerostomia), unstimulated salivary flow rate (USFR), hematological indexes, and medical history. The Kappa consistency test and Spearman's correlation coefficient were used to analyze the data. Results: There was a very low consistency between the reduced USFR and xerostomia in SS patients. The reduced USFR was positively correlated with the course of SS, ANA antibody, IgM, and the comorbidity of autoimmune liver disease. Conclusion: The consistency of USFR and xerostomia in SS patients was poor. Although USFR has a certain predictive and monitoring value for SS, it may be influenced by multiple factors. Understanding the risk factors influencing USFR and implementing targeted intervention would be helpful for oral health management of SS patients.

Key words: Sjögren's syndrome, unstimulated salivary flow rate, IgM, xerostomia, autoimmune liver disease, SSA, SSB

WEI Minghui, WANG Yuanyuan, WANG Yuhong, WANG Xinwen, DU Wanglei. Consistency of Salivary Flow Rate and Xerostomia in Patients with Sjögren's Syndrome[J]. Journal of Oral Science Research, 2023, 39(8): 751-754.

References

[1] 中华医学会风湿病学会. 干燥综合征诊断及治疗诊治指南[J]. 中华风湿病学杂志,2010,14(11):766-768.
[2] Pedersen AML, Sørensen CE, Proctor GB, et al. Salivary secretion in health and disease [J]. J Oral Rehabil, 2018, 45(9):730-746.
[3] Cartee DL, Maker S, Dalonges D, et al. Sjögren's syndrome: Oral manifestations and treatment, a dental perspective [J]. Int J Dent Hyg, 2015, 89(6):365-371.
[4] 俞光岩,宿骞,张艳,等. 唾液腺疾病与全身系统性疾病的相关性[J]. 北京大学学报(医学版),2023,55(1):1-7.
[5] 张文,厉小梅,徐东,等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志,2020,59(4):269-273.
[6] Bolstad AI, Skarstein K. Epidemiology of Sjögren's syndrome from an oral perspective [J]. Curr Oral Health Rep, 2016, 3(4):328-336.
[7] Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies [J]. Ann Rheum Dis, 2020, 79(1):3-18.
[8] 胡朝军,周仁芳,张蜀澜. 抗核抗体检测的临床应用专家共识[J]. 中华检验医学杂志,2018,41(4):275-280.
[9] Lacombe V, Lacout C, Lozac'h P, et al. Unstimulated whole saliva flow for diagnosis of primary Sjögren's syndrome: time to revisit the threshold [J]. Arthritis Res Ther, 2020, 22(1):38-40.
[10] Maliska M. The role of Epstein Barr virus infection in primary Sjögren's syndrome [J]. Curr Opin Rheumatol, 2019, 31(5):475-483.
[11] Houen G, Trier NH. Epstein-Barr virus and systemic autoimmune diseases [J]. Front Immunol, 2021, 11:587380.
[12] Nakamura H, Kawakami A. What is the evidence for Sjögren's syndrome being triggered by viral infection? Subplot: infections that cause clinical features of Sjögren's syndrome [J]. Curr Opin Rheumatol, 2016, 28(4):390-397.
[13] Liu Z, Chu A. Sjögren's syndrome and viral infections [J]. Rheumatol Ther, 2021, 8(3):1051-1059.
[14] de Oliveira NC, de Oliveira TC, Klamas VC, et al. Salivary flow, amylase, and total protein in hospitalized patients with HIV infection/AIDS complications [J]. Afr Health Sci, 2020, 20(2):597-604.
[15] Chowdhury F, Grigoriadou S, Bombardieri M. Severity of COVID-19 infection in primary Sjögren's syndrome and the emerging evidence of COVID-19-induced xerostomia [J]. Clin Exp Rheumatol, 2021, 133(6):215-222.